REZENOPY™ Resources
How To Order
REZENOPYTM is a prescription-only product available for purchase by healthcare organizations, pharmacies, public health agencies, and other authorized purchasers. Pricing varies based on your contract status, order volume, and purchasing channel. REZENOPY™ is FDA-approved and distributed in accordance with U.S. pharmaceutical supply chain regulations.
Prescribers & Pharmacists
Below you’ll find quick access to the clinical and product information you need to confidently recommend and dispense REZENOPY, along with naloxone resources to help educate your patients and caregivers on its proper use in an overdose emergency.
Implementation Resources & Education Materials
Equipping your patients and caregivers with naloxone resources is essential to reducing opioid overdose deaths in today’s fentanyl-driven landscape. The information below is designed to help you support your patients with practical tools and evidence-based education.
Facts & Figures
The opioid overdose epidemic continues to evolve, driven increasingly by highly potent synthetic opioids such as fentanyl that demand updated clinical approaches and response strategies. The resources below offer data-driven insights to help inform your practice and patient conversations.
Frequently Asked Questions
REZENOPY (10 mg naloxone) supports strategies to reduce Multiple Naloxone Administration (MNA) by delivering the highest-strength naloxone per nasal spray available. It is intended to provide robust opioid receptor antagonism in overdose situations involving potent, synthetic opioids, potentially reducing the reliance on multiple successive doses of lower-strength formulations. Discover more about the 10 mg difference.
Full clinical and dispensing resources are available at REZENOPY.com, including:
- Prescribing Information (PI): Available as a downloadable PDF or viewable online via DailyMed.
- Product Profile: A pharmacist-focused, downloadable resource covering product specifications, wholesaler item numbers (Cencora, Cardinal Health, McKesson, BioRidge), and WAC pricing.
- Customer Service: Reach the Scienture team at 1-888-353-0221 for additional product questions.
In a pharmacokinetic study of 30 healthy adult volunteers exposed to one spray of REZENOPY nasal spray, adverse reactions of abdominal pain upper, nasopharyngitis and dysgeusia were observed. For the full Prescribing Information and additional information about adverse reactions, see section 6 of DailyMed.
Yes. REZENOPY is contraindicated in patients with known hypersensitivity to naloxone hydrochloride or any of its ingredients.1 Key considerations include:
- Opioid-dependent patients: Administration may precipitate opioid withdrawal, which can be life-threatening in neonates if not recognized and treated promptly.
- Partial/mixed agonists: Reversal of respiratory depression caused by buprenorphine or pentazocine may be incomplete — larger or repeat doses may be required.
- Post-surgical use: Abrupt reversal of opioid depression may result in adverse cardiovascular effects, particularly in patients with pre-existing cardiovascular disorders.
- Continued surveillance: Due to naloxone’s duration of action relative to the opioid, patients should be monitored and additional doses administered as needed while awaiting emergency medical assistance.
For complete prescribing information, including full safety information, please see the Full Prescribing Information.
REZENOPY is indicated as an opioid antagonist for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system (CNS) depression in adult and pediatric patients. It is intended for immediate administration as emergency therapy in settings where opioids may be present. It is not a substitute for emergency medical care.1
REZENOPY (naloxone HCl) nasal spray 10 mg delivers the highest FDA-approved concentration of naloxone nasal spray available on the U.S. market — 10 mg per spray at a concentration of 10 mg/0.11 mL.1 It is a pre-filled, single-dose intranasal spray dispensed as a two-pack (NDC: 83245-003-01), manufactured in the U.S.A. by Scienture, LLC. See the 10 mg difference at www.REZENOPY.com.
You can download the REZENOPY product profile for detailed information on this high-dose naloxone nasal spray, designed to rapidly reverse opioid overdose in emergency and clinical settings. The profile includes key procurement details to help inform your purchasing decision.
Pricing for REZENOPY varies based on your contract status, order volume, and purchasing channel. GPO members will typically receive pricing through their existing contract terms. Non-GPO buyers are encouraged to contact our sales team to discuss pricing specific to their organization’s needs. Contact our sales team for more information.
Yes. Non-GPO buyers can purchase REZENOPY by contacting our commercial team directly to request purchasing information and discuss available options. We work with a range of buyers outside of GPO contracts.
Submit a request to have a Scienture representative contact you >
REZENOPY is distributed through authorized pharmaceutical wholesalers, who fulfill and ship orders directly to purchasing organizations. To get started, select a wholesaler from our authorized wholesaler list and place your order through them. GPO members should order through their contracted pharmaceutical wholesaler. See our How to Order Resources >
REZENOPY is available for purchase by healthcare organizations, pharmacies, public health agencies, and other authorized purchasers. As a prescription-only product, it is distributed in accordance with U.S. pharmaceutical supply chain regulations. If you’re unsure whether your organization qualifies, contact our commercial team for guidance.
References
- REZENOPY™ (naloxone HCl) nasal spray 10 mg [prescribing information]. Commack, NY; Scienture, LLC 2025.
